Drug class
Immunosuppressive Agents clinical trials
A class of medicines: the studies that test any of its 54 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the immunosuppressive agents studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
And 14 more, each tested in fewer studies.
Studies by the year they started
7,322 studies that test it; most in 2007 (345); 15 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 9 |
| 1991 | 10 |
| 1992 | 5 |
| 1993 | 13 |
| 1994 | 21 |
| 1995 | 28 |
| 1996 | 42 |
| 1997 | 56 |
| 1998 | 97 |
| 1999 | 119 |
| 2000 | 147 |
| 2001 | 154 |
| 2002 | 205 |
| 2003 | 237 |
| 2004 | 276 |
| 2005 | 303 |
| 2006 | 338 |
| 2007 | 345 |
| 2008 | 326 |
| 2009 | 342 |
| 2010 | 340 |
| 2011 | 299 |
| 2012 | 304 |
| 2013 | 304 |
| 2014 | 292 |
| 2015 | 316 |
| 2016 | 265 |
| 2017 | 263 |
| 2018 | 226 |
| 2019 | 214 |
| 2020 | 240 |
| 2021 | 227 |
| 2022 | 195 |
| 2023 | 208 |
| 2024 | 192 |
| 2025 | 183 |
| 2026 | 181 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1,671 · Other 5,737
M.D. Anderson Cancer Center (247) · National Cancer Institute (NCI) (224) · Novartis Pharmaceuticals (179) · Fred Hutchinson Cancer Center (144) · Astellas Pharma Inc (112) · Memorial Sloan Kettering Cancer Center (108) · National Institute of Allergy and Infectious Diseases (NIAID) (86) · City of Hope Medical Center (79)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 7,408
- Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07775313Written as Busulfan
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingPhase 2National Cancer Institute (NCI)NCT07524530Written as Cyclophosphamide
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06383572Written as Cyclophosphamide
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Methotrexate
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Cyclophosphamide
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT02830724Written as Cyclophosphamide
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as CHOP
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as cyclophosphamide
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Busulfan
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554393Written as Cytarabine
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Cytarabine
- Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00977977Written as Oral Cyclosporine
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Fluorouracil
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as Fluorouracil
- Advancing Transplantation Outcomes in ChildrenRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06055608Written as Sirolimus
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06918990Written as Belatacept
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06058377Written as Cyclophosphamide
- TRACK-TBI Precision Medicine Part 3 - Option IIEnrolling by invitationPhase 2University of California, San FranciscoNCT06790095Written as Cyclosporine (CsA)
- Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated RejectionRecruitingNot applicableHospices Civils de LyonNCT03955172Written as Everolimus
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingPhase 3Incyte CorporationNCT06615050Written as Methotrexate (MTX)
See all 7,408 studies that test one of the immunosuppressive agents →
Codes
What other systems call Immunosuppressive Agents · ClinicalTrials.gg INT007653
- MeSH (NLM) D007166Immunosuppressive AgentsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D007166 | Immunosuppressive Agents | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.